Search results for " oncologia"

showing 10 items of 366 documents

The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients

2013

Tumour-associated Macrophages (TAM) present two different polarizations: classical (M1) characterized by immunostimulation activity and tumour suppression; alternative (M2) characterized by tumour promotion and immune suppression. In this retrospective study, we evaluated the correlation between the two forms of TAM with survival time in radically resected gastric cancer patients. A total of 52 chemo- and radio- naive patients were included. Two slides were prepared for each patient and double-stained for CD68/NOS2 (M1) or CD68/CD163 (M2) and five representative high-power fields per slide were evaluated for TAM count. The median value of the two macrophage populations density and the media…

Malemedicine.medical_specialtyPathologyMultivariate analysisSettore MED/06 - Oncologia MedicaKaplan-Meier EstimateGastroenterologyImmune systemM1 polarization; M2 polarization; gastric cancerGastrectomyStomach NeoplasmsInternal medicinemedicineHumanstumour associated macrophages M1 polarization M2 polarization prognostic factor gastric cancerRadical surgeryprognostic factorRetrospective Studiesbusiness.industryCD68MacrophagesM2 polarizationgastric cancerM1 polarizationCell PolarityCancerRetrospective cohort studyOriginal ArticlesCell BiologyMiddle AgedPrognosisM2 Macrophagemedicine.diseaseTreatment OutcomeMultivariate Analysistumour associated macrophagesMolecular MedicineFemalebusinessCD163Journal of Cellular and Molecular Medicine
researchProduct

Linfomas malignos primários nas glandulas salivares

2011

Primary malignant lymphomas in the salivary glands are relatively rare. Clinical presentation is not characteristic and the disease is often overlooked resulting in diagnosis and treatment delays. AIM: To stress the importance of the diagnostic process and combined management, we present a series of eight patients with malignant lymphoma of the parotid who were diagnosed only after surgery and managed with radiation and chemotherapy. METHODS: Retrospective series of patients with primary malignant lymphoma of the parotid gland managed with radiotherapy and diagnostic surgical partial resection. RESULTS: After treatment completion we achieved a loco-regional control rate of 87.5%. Toxicity w…

Malemedicine.medical_specialtyPathologyglândulas salivaresSettore MED/06 - Oncologia Medicamedicine.medical_treatmentsalivary glandsSettore MED/19 - Chirurgia PlasticalymphomaDiseaseradioterapiaSettore MED/29 - Chirurgia Maxillofaccialestomatognathic systemlymphoma parotid salivary gland non-Hodgkin surgeryHumansMedicineStage (cooking)linfomalinfoma não hodgkinradiotherapyneoplasias parotídeasAgedRetrospective StudiesAged 80 and overPharmacologyChemotherapybusiness.industryLymphoma Non-HodgkinRate controlMiddle AgedPartial resectionmedicine.diseaseCombined Modality Therapynon-hodgkinLymphomaParotid glandRadiation therapyparotid neoplasmsTreatment Outcomemedicine.anatomical_structureSettore MED/31 - OtorinolaringoiatriaFemaleRadiologybusiness
researchProduct

The incidence of hip, forearm, humeral, ankle, and vertebral fragility fractures in Italy: results from a 3-year multicenter study

2010

Introduction: We aimed to assess the incidence and hospitalization rate of hip and "minor" fragility fractures in the Italian population.Methods: We carried out a 3-year survey at 10 major Italian emergency departments to evaluate the hospitalization rate of hip, forearm, humeral, ankle, and vertebral fragility fractures in people 45 years or older between 2004 and 2006, both men and women. These data were compared with those recorded in the national hospitalizations database (SDO) to assess the overall incidence of fragility fractures occurring at hip and other sites, including also those events not resulting in hospital admissions.Results: We observed 29,017 fractures across 3 years, with…

Malemedicine.medical_specialtySettore MED/06 - Oncologia MedicaOsteoporosisImmunologyWristFractures BoneForearmCost of IllnessRheumatologymedicineSettore MED/33 - Malattie Apparato LocomotoreHumansImmunology and AllergyHumerusStatistics & numerical dataBoneAgedbusiness.industryhip fractures vertebral fracturesIncidence (epidemiology)Settore MED/34 - Medicina Fisica E RiabilitativaIncidenceAged; Cost of Illness; Female; Forearm Injuries; epidemiology/etiology; Fractures; Bone; Hip Injuries; Hospitalization; statistics /&/ numerical data; Humans; Humerus; injuries; Incidence; Italy; epidemiology; Male; Middle Aged; Osteoporosis; complications; Spinal Fracturesfragility fractures; osteoporosisfragility fracturesForearm InjuriesHumerusMiddle Agedmedicine.diseaseMale; Middle Aged; Hip Injuries; Humerus; Spinal Fractures; Cost of Illness; Female; Forearm Injuries; Italy; Hospitalization; Humans; Osteoporosis; Fractures Bone; Aged; IncidenceSurgeryHospitalizationmedicine.anatomical_structureItalyOrthopedic surgeryPhysical therapyOsteoporosisSpinal FracturesFemaleAnklebusinessFracturesHip InjuriesResearch ArticleArthritis Research & Therapy
researchProduct

The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prosta…

2017

Two new drugs, the CYP17 inhibitor abiraterone acetate and the androgen receptor (AR) antagonist enzalutamide, have recently shown to prolong OS prior chemotherapy or in docetaxel treated mCRPC patients, using steroidal therapy or placebo as control group. Updated analyses underlined the role of these new agents on two prostate-specific endpoints as radiographic progression-free survival (rPFS) and time to first skeletal-related event (tSRE). On the basis of these reports, we made an indirect comparison between abiraterone and enzalutamide. We obtained a clinically but not significant difference favouring enzalutamide over abiraterone in terms of rPFS (HR 0.48, 95% CI 0.22–1.02). No signi…

Malemedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentUrologyAbiraterone AcetateBone NeoplasmsAbiraterone; Enzalutamide; mCRPC; rPFS; tSRE; Hematology; Oncology; Geriatrics and GerontologyPlaceboDisease-Free Survivallaw.invention03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineRandomized controlled triallawNitrilesPhenylthiohydantoinEnzalutamideAndrogen Receptor AntagonistsMedicineEnzalutamideCytochrome P-450 Enzyme InhibitorsHumans030212 general & internal medicineProgression-free survivalAbirateronetSRERandomized Controlled Trials as TopicChemotherapybusiness.industryAbiraterone acetateHematologymCRPCmedicine.diseaseProstatic Neoplasms Castration-ResistantTreatment OutcomechemistryDocetaxelrPFSOncology030220 oncology & carcinogenesisBenzamidesDisease ProgressionGeriatrics and Gerontologybusinessmedicine.drugCritical reviews in oncology/hematology
researchProduct

Alla ricerca della sicurezza e della qualità: il modello di miglioramento dell'Oncologia Medica nel Policlinico Universitario di Palermo

2015

[In search of safety and quality: the improvement model proposed by the Oncology Department of the Palermo University] Over the past 20 years the field of oncology has product therapeutic innovations that have radically changed the prognosis of the most prevalent malignancies, since introduction of so-called targeted molecular agents. As a result of these changes, also the management of cancer patients has become more complex requiring technologies and skills that involve many professionals (medical oncologists, biologists, molecular geneticists, surgeons, pathologists, radiologists, nurses and psychologists), each engaged in a different stage of the disease, with the common goal of ensurin…

Management of cancer patientmedicine.medical_specialtyChemotherapy; Management of cancer patients; Safety; Dragon Boat; RehabilitationSettore MED/06 - Oncologia Medicabusiness.industryRehabilitationAlternative medicineDiseaseSettore MED/42 - Igiene Generale E ApplicataUniversity hospitalSurgeryNursingRisk Management; Healthcare OrganizationmedicineChemotherapyDragon BoatSafetyQuality of careMedical prescriptionbusinessPratica Medica & Aspetti Legali
researchProduct

Mediterranean diet and cancer: epidemiological evidence and mechanism of selected aspects

2013

Background: Populations living in the area of the Mediterranean Sea suffered by decreased incidence of cancer compared with those living in the regions of northern Europe and US countries, attributed to healthier dietary habits. Nowadays, we are assisting to a moving away from the traditional Mediterranean dietary pattern, but whether this changing is influencing risk of cancers is still unclear. The aim of the study was to review recent evidence on potential relationship between the adherence to the Mediterranean diet and cancer. Discussion: The most recent pooled analyses of epidemiological studies supported strongly the hypothesis that the Mediterranean diet may play a role in preventing…

Mediterranean climatemedicine.medical_specialtySettore MED/09 - Medicina InternaMediterranean dietSettore MED/06 - Oncologia MedicaDiet MediterraneanMediterranean seaEnvironmental healthNeoplasmsEpidemiologymedicineHumansSettore MED/49 - Scienze Tecniche Dietetiche ApplicateTraditional medicineMechanism (biology)business.industryDiet Cancer Mediterranean dietIncidence (epidemiology)CancerGeneral MedicineDietary patternmedicine.diseaseSurgeryFoodSurgerybusinessResearch Article
researchProduct

Exploratory study about needs of disease progression in cancer patients

Background: Oncological disease progression can be difficult to manage for physicians, due to therapeutic switch after a previous treatments’ failure, but also because oncologist have to be linked with information about clinical conditions for patient reassurance. Our research considers person an integrated system, looking at fundamental needs of patients, according to theoretical and empirical basis of Neo-functionalism in psychology. Several studies report more unmet needs in patients affected by cancer, despite an increased attention about bad news communication. Previous studies in the field of healthcare have shown that both communication and psychological characteristics of patients a…

Needs cancer disease progression illness perception quality of lifeSettore MED/06 - Oncologia Medica
researchProduct

Cancer chemotherapy in the older cancer patient.

2009

This article reviews the principles of systemic cancer treatment in older individuals. These include: assessment of physiologic age with a comprehensive geriatric assessment (CGA), adjustment of chemotherapy doses to the patient's renal function, and prevention of myelotoxicity with hemopoietic growth factors. Other complications that become more common with age include mucositis, peripheral neuropathy and cardiomyopathy. Two chronic complications of chemotherapy become more common with age, including myelodysplasia and chronic cardiomyopathy. The goal of systemic cancer treatment in the older person should include prolongation of active life-expectancy and compression of morbidity in addit…

Nephrologymedicine.medical_specialtyAgingSettore MED/06 - Oncologia MedicaUrologymedicine.medical_treatmentCardiomyopathySystemic treatmentAntineoplastic AgentsKidneyMedical OncologyPatient Care PlanningElderlyLife ExpectancyInternal medicineNeoplasmsmedicineMucositisChemotherapyHumansIntensive care medicineGeriatric AssessmentCancerAgedAged 80 and overChemotherapybusiness.industryKidney metabolismCancermedicine.diseasePeripheral neuropathyTreatment OutcomeOncologyCompression of morbiditybusinessUrologic oncology
researchProduct

Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta…

2019

Background: Tissue evaluation for RAS (KRAS or NRAS) gene status in metastatic colorectal cancer (mCRC) patients represent the standard of care to establish the optimal therapeutic strategy. Unfortunately, tissue biopsy is hampered by several critical limitations due to its invasiveness, difficulty to access to disease site, patient’s compliance and, more recently, neoplastic tissue spatial and temporal heterogeneity. Methods: The authors performed a systematic literature review to identify available trials with paired matched tissue and ctDNA RAS gene status evaluation. The authors searched EMBASE, MEDLINE, Cochrane, www.ClinicalTrials.gov , and abstracts from international meetings. In to…

Neuroblastoma RAS viral oncogene homologOncologymedicine.medical_specialtyStandard of careColorectal cancerSettore MED/06 - Oncologia Medicamedicine.disease_causelcsh:RC254-282meta-analysi03 medical and health sciences0302 clinical medicineInternal medicinemedicineLiquid biopsy030304 developmental biologyTherapeutic strategycirculating tumor DNAcirculating tumor DNA; diagnostic accuracy; liquid biopsy; meta-analysis; metastatic colorectal cancer; RAS0303 health sciencesliquid biopsybusiness.industrymetastatic colorectal cancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthmeta-analysisOncologyCirculating tumor DNA030220 oncology & carcinogenesisMeta-analysisdiagnostic accuracyKRASbusinessRAS
researchProduct

Targeted Therapies in Hepatocellular Carcinoma

2014

Abstract: The onset of hepatocellular carcinoma (HCC) is related to the development of non-neoplastic liver disease, such as viral infections and cirrhosis. Even though patients with chronic liver diseases undergo clinical surveillance for early diagnosis of HCC, this cancer is often diagnosed in advanced stage. In this case locoregional treatment is not possible and systemic therapies are the best way to control it. Until now sorafenib, a Raf and multi-kinase inhibitor has been the best, choice to treat HCC systemically. It showed a survival benefit in multicenter phase III trials. However the proper patient setting to treat is not well defined, since the results in Child-Pugh B patients a…

NiacinamideVascular Endothelial Growth Factor ACarcinoma HepatocellularSettore MED/06 - Oncologia MedicaCirrhosis hepatocellular carcinoma liver disease targeted therapiesAntineoplastic AgentsBiochemistryDrug DiscoveryAnimalsHumansMolecular Targeted TherapyBiologyProtein Kinase InhibitorsPharmacologyPharmacology. TherapyPhenylurea CompoundsTOR Serine-Threonine KinasesLiver NeoplasmsOrganic ChemistryAntibodies MonoclonalSorafenibdigestive system diseasesErbB ReceptorsChemistryLiverMolecular MedicineCurrent Medicinal Chemistry
researchProduct